Solid Biosciences doses five participants in Friedreich’s ataxia gene therapy trial
SLDB•Solid Biosciences said five participants have been dosed in its Phase 1b FALCON trial of SGT-212 for Friedreich’s ataxia, with no treatment-related serious adverse events as of October 5, 2026. The European Commission granted SGT-212 orphan designation, and initial clinical data are expected in the first quarter of 2027.
1. Trial update
Solid Biosciences said five participants have been dosed in the Phase 1b FALCON trial of SGT-212, its investigational gene therapy for Friedreich’s ataxia. As of October 5, 2026, no treatment-related serious adverse events had been reported; initial clinical data are expected in the first quarter of 2027. The European Commission granted SGT-212 orphan designation.
